Exact Mass: 477.172
Exact Mass Matches: 477.172
Found 500 metabolites which its exact mass value is equals to given mass value 477.172
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
CB3717
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents
Furcelleran
Furcelleran is an emulsifier, stabiliser, thickening agent. Furcelleran salts prepd. by increasing the concentration of the naturally occurring cations (ammonium, calcium, potassium or sodium) have similar utility. Emulsifier, stabiliser, thickening agent. Furcelleran salts prepd. by increasing the concentration of the naturally occurring cations (ammonium, calcium, potassium or sodium) have similar utility
(2S,3R)-2-(4-{2-[(3S,4S)-3,4-Dimethylpyrrolidin-1-YL]ethoxy}phenyl)-3-(4-hydroxyphenyl)-2,3-dihydro-1,4-benzoxathiin-6-OL
10-Propargyl-5,8-dideazafolic acid
4-(7-(((1R)-1-((3-Chloro-2-thienyl)methyl)propyl)amino)-3H-imidazo(4,5-b)pyridin-3-yl)-N-ethyl-2,3-dihydroxycyclopentanecarboxamide, (1S,2R,3S,4R)-
Isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylate
Batimastat
5-O-Benzyl 3-O-ethyl 2-methyl-6-phenyl-4-(2-phenylethynyl)-3,4-dihydropyridine-3,5-dicarboxylate
Pralatrexate
ritanserin
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of 5-HT2 receptor, with an IC50 of 0.9 nM, less active on Histamine H1, Dopamine D2, Adrenergic α1, Adrenergic α2 receptors[1].
(S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide
7-hydroxy-1-(3,4-dihydroxy)-N2,N3-bis(4-hydroxyphenethyl)-6,8-dimethoxy-1,2-dihydronaphthalene-2,3-dicarboxamide
Pralatrexate
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor
Ser Gln Asp Glu
ritanserin
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Ritanserin (R 55667) is a highly potent, relatively selective, orally active, long acting antagonist of 5-HT2 receptor, with an IC50 of 0.9 nM, less active on Histamine H1, Dopamine D2, Adrenergic α1, Adrenergic α2 receptors[1].
Ala Cys Glu Arg
Ala Cys Arg Glu
Ala Asp Ser Trp
Ala Asp Trp Ser
Ala Glu Cys Arg
Ala Glu Met Gln
Ala Glu Gln Met
Ala Glu Arg Cys
Ala Met Glu Gln
Ala Met Gln Glu
Ala Gln Glu Met
Ala Gln Met Glu
Ala Arg Cys Glu
Ala Arg Glu Cys
Ala Ser Asp Trp
Ala Ser Trp Asp
Ala Trp Asp Ser
Ala Trp Ser Asp
Cys Ala Glu Arg
Cys Ala Arg Glu
Cys Cys Pro Arg
Cys Cys Arg Pro
Cys Asp Ile Gln
Cys Asp Leu Gln
Cys Asp Gln Ile
Cys Asp Gln Leu
Cys Glu Ala Arg
Cys Glu Ile Asn
Cys Glu Leu Asn
Cys Glu Asn Ile
Cys Glu Asn Leu
Cys Glu Gln Val
Cys Glu Arg Ala
Cys Glu Val Gln
Cys Ile Asp Gln
Cys Ile Glu Asn
Cys Ile Asn Glu
Cys Ile Gln Asp
Cys Lys Asn Asn
Cys Leu Asp Gln
Cys Leu Glu Asn
Cys Leu Asn Glu
Cys Leu Gln Asp
Cys Met Pro Gln
Cys Met Gln Pro
Cys Asn Glu Ile
Cys Asn Glu Leu
Cys Asn Ile Glu
Cys Asn Lys Asn
Cys Asn Leu Glu
Cys Asn Asn Lys
Cys Asn Asn Gln
Cys Asn Gln Asn
Cys Pro Cys Arg
Cys Pro Met Gln
Cys Pro Gln Met
Cys Pro Arg Cys
Cys Gln Asp Ile
Cys Gln Asp Leu
Cys Gln Glu Val
Cys Gln Ile Asp
Cys Gln Leu Asp
Cys Gln Met Pro
Cys Gln Asn Asn
Cys Gln Pro Met
Cys Gln Val Glu
Cys Arg Ala Glu
Cys Arg Cys Pro
Cys Arg Glu Ala
Cys Arg Pro Cys
Cys Val Glu Gln
Cys Val Gln Glu
Asp Ala Ser Trp
Asp Ala Trp Ser
Asp Cys Ile Gln
Asp Cys Leu Gln
Asp Cys Gln Ile
Asp Cys Gln Leu
Asp Asp Gln Thr
Asp Asp Thr Gln
Asp Glu Asn Thr
Asp Glu Gln Ser
Asp Glu Ser Gln
Asp Glu Thr Asn
Asp Gly Met Arg
Asp Gly Arg Met
Asp Gly Thr Trp
Asp Gly Trp Thr
Asp Ile Cys Gln
Asp Ile Gln Cys
Asp Leu Cys Gln
Asp Leu Gln Cys
Asp Met Asn Val
Asp Met Val Asn
Asp Asn Glu Thr
Asp Asn Met Val
Asp Asn Thr Glu
Asp Asn Val Met
Asp Gln Cys Ile
Asp Gln Cys Leu
Asp Gln Asp Thr
Asp Gln Glu Ser
Asp Gln Ile Cys
Asp Gln Leu Cys
Asp Gln Ser Glu
Asp Gln Thr Asp
Asp Ser Ala Trp
Asp Ser Glu Gln
Asp Ser Gln Glu
Asp Ser Trp Ala
Asp Thr Asp Gln
Asp Thr Glu Asn
Asp Thr Gly Trp
Asp Thr Asn Glu
Asp Thr Gln Asp
Asp Thr Trp Gly
Asp Val Met Asn
Asp Val Asn Met
Asp Trp Ala Ser
Asp Trp Gly Thr
Asp Trp Ser Ala
Asp Trp Thr Gly
Glu Ala Met Gln
Glu Ala Gln Met
Glu Cys Ile Asn
Glu Cys Leu Asn
Glu Cys Asn Ile
Glu Cys Asn Leu
Glu Cys Gln Val
Glu Cys Val Gln
Glu Asp Asn Thr
Glu Asp Gln Ser
Glu Asp Ser Gln
Glu Asp Thr Asn
Glu Glu Asn Ser
Glu Glu Ser Asn
Glu Gly Ser Trp
Glu Gly Trp Ser
Glu Ile Cys Asn
Glu Ile Asn Cys
Glu Leu Cys Asn
Glu Leu Asn Cys
Glu Met Ala Gln
Glu Met Gln Ala
Glu Asn Cys Ile
Glu Asn Cys Leu
Glu Asn Asp Thr
Glu Asn Glu Ser
Glu Asn Ile Cys
Glu Asn Leu Cys
Glu Asn Ser Glu
Glu Asn Thr Asp
Glu Gln Ala Met
Glu Gln Cys Val
Glu Gln Asp Ser
Glu Gln Met Ala
Glu Gln Ser Asp
Glu Gln Val Cys
Glu Ser Asp Gln
Glu Ser Glu Asn
Glu Ser Gly Trp
Glu Ser Asn Glu
Glu Ser Gln Asp
Glu Ser Trp Gly
Glu Thr Asp Asn
Glu Thr Asn Asp
Glu Val Cys Gln
Glu Val Gln Cys
Glu Trp Gly Ser
Glu Trp Ser Gly
Gly Asp Thr Trp
Gly Asp Trp Thr
Gly Glu Ser Trp
Gly Glu Trp Ser
Gly Ser Glu Trp
Gly Ser Trp Glu
Gly Thr Asp Trp
Gly Thr Trp Asp
3,5-Pyridinedicarboxylic acid, 2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]
Gly Trp Asp Thr
Gly Trp Glu Ser
Gly Trp Ser Glu
Gly Trp Thr Asp
Ile Cys Asp Gln
Ile Cys Glu Asn
Ile Cys Asn Glu
Ile Cys Gln Asp
Ile Asp Cys Gln
Ile Asp Gln Cys
Ile Glu Cys Asn
Ile Glu Asn Cys
Ile Asn Cys Glu
Ile Asn Glu Cys
Ile Gln Cys Asp
Ile Gln Asp Cys
Leu Cys Asp Gln
Leu Cys Glu Asn
Leu Cys Asn Glu
Leu Cys Gln Asp
Leu Asp Cys Gln
Leu Asp Gln Cys
Leu Glu Cys Asn
Leu Glu Asn Cys
Leu Asn Cys Glu
Leu Asn Glu Cys
Leu Gln Cys Asp
Leu Gln Asp Cys
Met Ala Glu Gln
Met Ala Gln Glu
Met Cys Pro Gln
Met Cys Gln Pro
Met Asp Asn Val
Met Asp Val Asn
Met Glu Ala Gln
Met Glu Gln Ala
Met Asn Asp Val
Met Asn Val Asp
Met Pro Cys Gln
Met Pro Gln Cys
Met Gln Ala Glu
Met Gln Cys Pro
Met Gln Glu Ala
Met Gln Pro Cys
Met Val Asp Asn
Met Val Asn Asp
Asn Cys Glu Ile
Asn Cys Glu Leu
Asn Cys Ile Glu
Asn Cys Leu Glu
Asn Cys Asn Gln
Asn Cys Gln Asn
Asn Asp Glu Thr
Asn Asp Met Val
Asn Asp Thr Glu
Asn Asp Val Met
Asn Glu Cys Ile
Asn Glu Cys Leu
Asn Glu Asp Thr
Asn Glu Glu Ser
Asn Glu Ile Cys
Asn Glu Leu Cys
Asn Glu Ser Glu
Asn Glu Thr Asp
Asn Ile Cys Glu
Asn Ile Glu Cys
Asn Leu Cys Glu
Asn Leu Glu Cys
Asn Met Asp Val
Asn Met Val Asp
Asn Asn Cys Gln
Asn Asn Gln Cys
Asn Gln Cys Asn
Asn Gln Asn Cys
Asn Ser Glu Glu
Asn Thr Asp Glu
Asn Thr Glu Asp
Asn Val Asp Met
Asn Val Met Asp
Pro Cys Cys Arg
Pro Cys Met Gln
Pro Cys Gln Met
Pro Cys Arg Cys
Pro Met Cys Gln
Pro Met Gln Cys
Pro Gln Cys Met
Pro Gln Met Cys
Pro Arg Cys Cys
Gln Ala Glu Met
Gln Ala Met Glu
Gln Cys Asp Ile
Gln Cys Asp Leu
Gln Cys Glu Val
Gln Cys Ile Asp
Gln Cys Leu Asp
Gln Cys Met Pro
Gln Cys Asn Asn
Gln Cys Pro Met
Gln Cys Val Glu
Gln Asp Cys Ile
Gln Asp Cys Leu
Gln Asp Asp Thr
Gln Asp Glu Ser
Gln Asp Ile Cys
Gln Asp Leu Cys
Gln Asp Ser Glu
Gln Asp Thr Asp
Gln Glu Ala Met
Gln Glu Cys Val
Gln Glu Asp Ser
Gln Glu Met Ala
Gln Glu Ser Asp
Gln Glu Val Cys
Gln Ile Cys Asp
Gln Ile Asp Cys
Gln Leu Cys Asp
Gln Leu Asp Cys
Gln Met Ala Glu
Gln Met Cys Pro
Gln Met Glu Ala
Gln Met Pro Cys
Gln Asn Cys Asn
Gln Asn Asn Cys
Gln Pro Cys Met
Gln Pro Met Cys
Gln Ser Asp Glu
Gln Ser Glu Asp
Gln Thr Asp Asp
Gln Val Cys Glu
Gln Val Glu Cys
Arg Cys Cys Pro
Arg Cys Pro Cys
Arg Pro Cys Cys
Ser Ala Asp Trp
Ser Ala Trp Asp
Ser Asp Ala Trp
Ser Asp Glu Gln
Ser Asp Gln Glu
Ser Asp Trp Ala
Ser Glu Asp Gln
Ser Glu Glu Asn
Ser Glu Gly Trp
Ser Glu Asn Glu
Ser Glu Gln Asp
Ser Glu Trp Gly
Ser Gly Glu Trp
Ser Gly Trp Glu
Ser Asn Glu Glu
Ser Gln Glu Asp
Ser Trp Ala Asp
Ser Trp Asp Ala
Ser Trp Glu Gly
Ser Trp Gly Glu
Thr Asp Asp Gln
Thr Asp Glu Asn
Thr Asp Gly Trp
Thr Asp Asn Glu
Thr Asp Gln Asp
Thr Asp Trp Gly
Thr Glu Asp Asn
Thr Glu Asn Asp
Thr Gly Asp Trp
Thr Gly Trp Asp
Thr Asn Asp Glu
Thr Asn Glu Asp
Thr Gln Asp Asp
Thr Trp Asp Gly
Thr Trp Gly Asp
Val Cys Glu Gln
Val Cys Gln Glu
Val Asp Met Asn
Val Asp Asn Met
Val Glu Cys Gln
Val Glu Gln Cys
Val Met Asp Asn
Val Met Asn Asp
Val Asn Asp Met
Val Asn Met Asp
Val Gln Cys Glu
Val Gln Glu Cys
Trp Ala Asp Ser
Trp Ala Ser Asp
Trp Asp Ala Ser
Trp Asp Gly Thr
Trp Asp Ser Ala
Trp Asp Thr Gly
Trp Glu Gly Ser
Trp Glu Ser Gly
Trp Gly Asp Thr
Trp Gly Glu Ser
Trp Gly Ser Glu
Trp Gly Thr Asp
Trp Ser Ala Asp
Trp Ser Asp Ala
Trp Ser Glu Gly
Trp Ser Gly Glu
Trp Thr Asp Gly
Trp Thr Gly Asp
furcelleran
Vilazodone Hydrochloride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D049990 - Membrane Transport Modulators Vilazodone Hydrochloride (EMD 68843 Hydrochloride) is a serotonin transporter (SER) inhibitor and 5-HT1A receptor partial agonist.
2-Cyclopropyl-3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)quinoline
Batimastat
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C1970 - Matrix Metalloproteinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors D000970 - Antineoplastic Agents
Native Electrophorus electricus (electric eel) Acetylcholinesterase
5-Benzyl 3-ethyl 2-methyl-6-phenyl-4-(phenylethynyl)-1,4-dihydro-3,5-pyridinedicarboxylate
(S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide
10-Propargyl-5,8-dideazafolic acid
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents
O3-ethyl O5-(phenylmethyl) 2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylate
MRS-1191 is a potent and selective A3 adenosine receptor antagonist with a KB value of 92 nM, a Ki value of 31.4 nM for human A3 receptor and an IC50 of 120 nM for CHO cells[1]. MRS-1191 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
(3S)-3-[[[(2S)-1-[(2S)-2-[[(4-amino-3-chlorophenyl)-oxomethyl]amino]-3,3-dimethyl-1-oxobutyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-cyanopropanoic acid
Benzoic acid [5-(6-benzamido-9-purinyl)-3-fluoro-4-hydroxy-2-oxolanyl]methyl ester
N-({(2s)-1-[(3r)-3-Amino-4-(3-Chlorophenyl)butanoyl]pyrrolidin-2-Yl}methyl)-3-(Methylsulfonyl)benzamide
N-{(1s,2r)-1-Benzyl-3-[(Cyclopropylmethyl)(2-Furylsulfonyl)amino]-2-Hydroxypropyl}-N-Methylsuccinamide
(2S,3S)-2-[4-[2-[(3R,4R)-3,4-dimethylpyrrolidin-1-yl]ethoxy]phenyl]-3-(4-hydroxyphenyl)-2,3-dihydro-1,4-benzoxathiin-6-ol
Pradigastat sodium
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor
4-(7-(((1R)-1-((3-Chloro-2-thienyl)methyl)propyl)amino)-3H-imidazo(4,5-b)pyridin-3-yl)-N-ethyl-2,3-dihydroxycyclopentanecarboxamide, (1S,2R,3S,4R)-
(S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide
2-[2-Oxo-2-[4-(4-phenyl-1-phthalazinyl)-1-piperazinyl]ethyl]isoindole-1,3-dione
3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one
N-butan-2-yl-2-[[3-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-4-oxo-2-quinazolinyl]thio]acetamide
4-Nitrophenyl 4-(bis(4-methoxyphenyl)methyl)piperazine-1-carboxylate
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-phenoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid
[(3aS,4R,9bS)-1-(2-fluorophenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(4-phenoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-phenoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid
(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-6-oxo-5-pyridin-4-yl-12-(1,3-thiazol-2-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(2R,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2S,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2S,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,5S,6R)-5-[[(2,5-difluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,5S,6R)-5-[[(2,5-difluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-phenoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid
[(3aR,4R,9bR)-1-(2-fluorophenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(2S,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2R,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2S,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2R,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-[(2R,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-1,3-benzodioxole-5-carboxamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,5R,6S)-5-[[(2,5-difluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,5R,6S)-5-[[(2,5-difluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-phenoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid
(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-6-oxo-5-pyridin-4-yl-12-(1,3-thiazol-2-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(3aS,4S,9bS)-1-(2-fluorophenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
Butyl 4,7-DI(para-ethoxyphenyl)-1,2,5-thiadiazolo(3,4-C)pyridine-6-carboxylate
CP-346086
CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo[1].